Tags

Type your tag names separated by a space and hit enter

Difference in the plasma level of miR-628-3p in atopic dermatitis patients with/without atopic keratoconjunctivitis.
Immun Inflamm Dis. 2021 12; 9(4):1815-1819.II

Abstract

INTRODUCTION

Some but not all patients with atopic dermatitis (AD) present with allergic conjunctival disease (ACD) including severe types such as atopic keratoconjunctivitis (AKC) with/without giant papillae. We hypothesized that different factors are involved in the severity of ACD and AD. Recently we reported that hsa-miR-628-3p could affect the balance of innate immunity by suppressing pathogen-associated molecular patterns such as toll-like receptor 3 (TLR3), RIG-I, and MDA-5. We also reported that TLR3 positively regulates ocular surface- and skin inflammation such as contact dermatitis and AD. Here we compared the plasma level of miR-628-3p in AD patients with severe AKC with giant papillae and/or shield ulcers, with the level in healthy controls and AD patient without AKC or with very mild AKC.

METHODS

We used the plasma from 32 AD patients with severe AKC, from 40 healthy controls, and from 23 AD patient without AKC or with very mild AKC without giant papillae nor shield ulcers. Quantitative microRNA PCR assays were used to measure their plasma level of miR-628-3p.

RESULTS

We found that plasma miR-628-3p was upregulated in AD with severe AKC, but not in severe AD without severe AKC, nor in our healthy controls.

CONCLUSION

Our new findings suggest that the plasma miR-628-3p level may represent a marker to predict the presence of severe AKC in AD patients.

Links

PMC Free PDF

Authors+Show Affiliations

Ueta M
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Nishigaki H
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Komai S
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Sotozono C
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kinoshita S
Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

MeSH

ConjunctivaConjunctivitis, AllergicDermatitis, AtopicHumansKeratoconjunctivitisMicroRNAs

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34547828

Citation

Ueta, Mayumi, et al. "Difference in the Plasma Level of miR-628-3p in Atopic Dermatitis Patients With/without Atopic Keratoconjunctivitis." Immunity, Inflammation and Disease, vol. 9, no. 4, 2021, pp. 1815-1819.
Ueta M, Nishigaki H, Komai S, et al. Difference in the plasma level of miR-628-3p in atopic dermatitis patients with/without atopic keratoconjunctivitis. Immun Inflamm Dis. 2021;9(4):1815-1819.
Ueta, M., Nishigaki, H., Komai, S., Sotozono, C., & Kinoshita, S. (2021). Difference in the plasma level of miR-628-3p in atopic dermatitis patients with/without atopic keratoconjunctivitis. Immunity, Inflammation and Disease, 9(4), 1815-1819. https://doi.org/10.1002/iid3.536
Ueta M, et al. Difference in the Plasma Level of miR-628-3p in Atopic Dermatitis Patients With/without Atopic Keratoconjunctivitis. Immun Inflamm Dis. 2021;9(4):1815-1819. PubMed PMID: 34547828.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Difference in the plasma level of miR-628-3p in atopic dermatitis patients with/without atopic keratoconjunctivitis. AU - Ueta,Mayumi, AU - Nishigaki,Hiromi, AU - Komai,Seitaro, AU - Sotozono,Chie, AU - Kinoshita,Shigeru, Y1 - 2021/09/21/ PY - 2021/08/19/revised PY - 2021/07/14/received PY - 2021/09/04/accepted PY - 2021/9/22/pubmed PY - 2021/12/15/medline PY - 2021/9/21/entrez KW - allergy processes KW - epigenetics processes KW - human KW - mucosa tissues SP - 1815 EP - 1819 JF - Immunity, inflammation and disease JO - Immun Inflamm Dis VL - 9 IS - 4 N2 - INTRODUCTION: Some but not all patients with atopic dermatitis (AD) present with allergic conjunctival disease (ACD) including severe types such as atopic keratoconjunctivitis (AKC) with/without giant papillae. We hypothesized that different factors are involved in the severity of ACD and AD. Recently we reported that hsa-miR-628-3p could affect the balance of innate immunity by suppressing pathogen-associated molecular patterns such as toll-like receptor 3 (TLR3), RIG-I, and MDA-5. We also reported that TLR3 positively regulates ocular surface- and skin inflammation such as contact dermatitis and AD. Here we compared the plasma level of miR-628-3p in AD patients with severe AKC with giant papillae and/or shield ulcers, with the level in healthy controls and AD patient without AKC or with very mild AKC. METHODS: We used the plasma from 32 AD patients with severe AKC, from 40 healthy controls, and from 23 AD patient without AKC or with very mild AKC without giant papillae nor shield ulcers. Quantitative microRNA PCR assays were used to measure their plasma level of miR-628-3p. RESULTS: We found that plasma miR-628-3p was upregulated in AD with severe AKC, but not in severe AD without severe AKC, nor in our healthy controls. CONCLUSION: Our new findings suggest that the plasma miR-628-3p level may represent a marker to predict the presence of severe AKC in AD patients. SN - 2050-4527 UR - https://www.unboundmedicine.com/medline/citation/34547828/Difference_in_the_plasma_level_of_miR_628_3p_in_atopic_dermatitis_patients_with/without_atopic_keratoconjunctivitis_ DB - PRIME DP - Unbound Medicine ER -